surpass cvot tirzepatide results SURPASS-CVOT: Bests Dulaglutide for Cardiovascular Protection Reduction of prevalence of patients

In total, 100 participants with T2D who have been treated with liraglutide (0.91.8 mg/day in plan A) or dulaglutide (0.75 mg/week in plan B) for more than 12 weeks and have a glycated hemoglobin (HbA1c) level of 6.09.9% and a body mass index (BMI) of 22 kg/m 2 will be randomized to either continue using their existing GLP-1 receptor agonist or switch to subcutaneous semaglutide once weekly for 24 weeks

discuss goals, timeline, budget, alternatives If suitable: 2.5 mg weekly 4 weeks , injection teaching, side-effect toolkit, next review scheduled Titrate, track, and adjust Step up dose as tolerated

Med J Armed Forces India

The standard protocol in clinical trials escalated doses every 4 weeks

Is a GLP-1 medication even right for me

The olfactory system (smell) and gustatory system (taste) are closely linked